Practice parameter for the diagnosis and management of primary immunodeficiency

• Published in: Journal of allergy and clinical immunology Vol. 136; no. 5; pp. 1186 - 1205.e78
• Main Authors: Bonilla, Francisco A., MD, PhD, Khan, David A., MD, Ballas, Zuhair K., MD, Chinen, Javier, MD, PhD, Frank, Michael M., MD, Hsu, Joyce T., MD, Keller, Michael, MD, Kobrynski, Lisa J., MD, Komarow, Hirsh D., MD, Mazer, Bruce, MD, Nelson, Robert P., MD, Orange, Jordan S., MD, PhD, Routes, John M., MD, Shearer, William T., MD, PhD, Sorensen, Ricardo U., MD, Verbsky, James W., MD, PhD, Bernstein, David I., MD, Blessing-Moore, Joann, MD, Lang, David, MD, Nicklas, Richard A., MD, Oppenheimer, John, MD, Portnoy, Jay M., MD, Randolph, Christopher R., MD, Schuller, Diane, MD, Spector, Sheldon L., MD, Tilles, Stephen, MD, Wallace, Dana, MD, Khan, David, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2015; Elsevier Limited
• Subjects: Advisory Committees; Allergies; Allergy and Immunology; Animals; Clinical Trials as Topic; Conflicts of interest; Disease Management; Evidence-Based Medicine; Humans; Immunologic Deficiency Syndromes - diagnosis; Immunologic Deficiency Syndromes - therapy; Laboratories; Physicians; Teenagers; Ohio; SS; JCAAI; Summary statement; Severe combined immunodeficiency; American Academy of Allergy, Asthma & Immunology; Hematopoietic stem cell therapy; SCID; American College of Allergy, Asthma & Immunology; Joint Council of Allergy, Asthma & Immunology; ACAAI; Primary immunodeficiency disease; AAAAI; PIDD; HSCT
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2015.04.049

The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for establishing the “Practice parameter for the diagnosis and management of primary immunodeficiency.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.